HK1140217A1 - The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases - Google Patents

The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases

Info

Publication number
HK1140217A1
HK1140217A1 HK10106855.9A HK10106855A HK1140217A1 HK 1140217 A1 HK1140217 A1 HK 1140217A1 HK 10106855 A HK10106855 A HK 10106855A HK 1140217 A1 HK1140217 A1 HK 1140217A1
Authority
HK
Hong Kong
Prior art keywords
neovasculature
fibrinogen
antigen
tumour metastases
metastases
Prior art date
Application number
HK10106855.9A
Other languages
English (en)
Inventor
Dario Neri
Jascha Rybak
Christoph Roesli
Alessandra Villa
Giovanni Neri
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Publication of HK1140217A1 publication Critical patent/HK1140217A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
HK10106855.9A 2007-04-02 2010-07-14 The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases HK1140217A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90958007P 2007-04-02 2007-04-02
US94856407P 2007-07-09 2007-07-09
PCT/IB2008/000965 WO2008120101A2 (en) 2007-04-02 2008-03-31 The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases

Publications (1)

Publication Number Publication Date
HK1140217A1 true HK1140217A1 (en) 2010-10-08

Family

ID=39791007

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13112184.6A HK1184794A1 (zh) 2007-04-02 2010-07-14 與腫瘤轉移的新生血管有關的纖連蛋白的 抗原
HK10106855.9A HK1140217A1 (en) 2007-04-02 2010-07-14 The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13112184.6A HK1184794A1 (zh) 2007-04-02 2010-07-14 與腫瘤轉移的新生血管有關的纖連蛋白的 抗原

Country Status (13)

Country Link
US (5) US8263041B2 (es)
EP (2) EP2653478B1 (es)
JP (2) JP5221641B2 (es)
KR (1) KR101515243B1 (es)
CN (2) CN101687923B (es)
AU (1) AU2008234615B2 (es)
BR (1) BRPI0809989B8 (es)
CA (1) CA2682851C (es)
EA (2) EA018985B1 (es)
ES (2) ES2402171T3 (es)
HK (2) HK1184794A1 (es)
MX (1) MX2009010639A (es)
WO (1) WO2008120101A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2402171T3 (es) 2007-04-02 2013-04-29 Philogen S.P.A. El antígeno ED-A del fibrinógeno está asociado con la neovasculatura de las metástasis tumorales
WO2009013619A2 (en) * 2007-07-25 2009-01-29 Philogen S.P.A The ed-a antigen of fibrinogen is associated with the neovas culature of tumor metastases
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
PL3281952T3 (pl) 2007-10-30 2020-11-16 Philogen S.P.A. Antygen związany z reumatoidalnym zapaleniem stawów
US20110318302A1 (en) 2009-01-07 2011-12-29 Kathrin Schwager Cancer Treatment
US9527907B2 (en) 2009-01-07 2016-12-27 Philogen S.P.A. Antigens associated with endometriosis, psoriatic arthritis and psoriasis
EP2947096B1 (en) 2009-08-05 2018-11-28 Philogen S.p.A. Targeting of bone marrow neovasculature
WO2011156639A1 (en) * 2010-06-10 2011-12-15 The Regents Of The University Of California Eiiia and eiiib segments of fibronectin regulate stem cell fate
JP5548872B2 (ja) * 2010-08-26 2014-07-16 株式会社島津製作所 大腸がん肝転移マーカー、及び試料中の大腸がん肝転移マーカーの分析方法
AU2011307236A1 (en) 2010-09-29 2013-03-28 Philogen S.P.A. Thiazolidine linker for the conjugation of drugs to antibodies
WO2013014149A1 (en) 2011-07-27 2013-01-31 Philogen S.P.A. Il-12 immunoconjugate
PL2903629T3 (pl) * 2012-10-03 2019-12-31 Philogen S.P.A. Koniugat przeciwciała do zastosowania w leczeniu nieswoistego zapalenia jelita
AU2014360946B2 (en) 2013-12-12 2020-06-25 Umc Utrecht Holding B.V. Immunoglobulin-like molecules directed against fibronectin-EDA
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
PE20180797A1 (es) 2015-07-16 2018-05-09 Philogen Spa Inmunoconjugados de il22
US20190269791A1 (en) 2016-10-17 2019-09-05 Pfizer Inc. Anti-edb antibodies and antibody-drug conjugates
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
WO2018224550A1 (en) 2017-06-07 2018-12-13 Philogen S.P.A Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
MX2021014867A (es) * 2019-06-03 2022-03-25 Univ Chicago Metodos y composiciones para el tratamiento del cancer con adyuvantes dirigidos al cancer.
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
CA3148121A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Materials and methods for improved single chain variable fragments
WO2022018126A1 (en) 2020-07-22 2022-01-27 Philogen S.P.A. Treatment of pulmonary hypertension
CN114350518B (zh) * 2022-01-19 2023-01-13 广东乾晖生物科技有限公司 仿生肝微流控细胞培养-药物筛选芯片
WO2023175077A1 (en) 2022-03-17 2023-09-21 Philogen S.P.A Anti-ed-a antibodies for the treatment of pulmonary hypertension

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5420012A (en) 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
FI892197A (fi) * 1989-05-08 1990-11-09 Locus Oy Foerfarande foer detektering av tumoerer.
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
EP0580859A4 (en) * 1991-03-26 1994-09-14 Otsuka Pharma Co Ltd Anti-eda monoclonal antibody
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
CA2351346C (en) 1998-12-10 2015-09-01 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
PT1719528E (pt) 2000-02-24 2012-01-06 Philogen Spa Composições e métodos para tratamento de angiogénese em lesões patológicas
CA2404919A1 (en) 2000-04-06 2002-10-01 Kyowa Hakko Kogyo Co. Ltd. Diagnostic and therapeutic agents for rheumatoid arthritis
AU5867901A (en) 2000-05-04 2001-11-12 Philogen S.R.L. Method for detecting tumors
US20020197700A1 (en) 2000-09-07 2002-12-26 Schering Ag Receptor of the EDb-fibronectin domains
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
BR0306715A (pt) * 2002-01-03 2004-12-28 Schering Ag Métodos para diagnóstico e tratamento de tumores
WO2004000216A2 (en) 2002-06-21 2003-12-31 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US7560095B2 (en) 2003-04-22 2009-07-14 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
CA2533878A1 (en) 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
ATE534750T1 (de) 2004-07-30 2011-12-15 Adeza Biomedical Corp Onkofetales fibronektin als zervixkarzinom-marker
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP1817345B9 (en) 2004-11-09 2009-11-18 Philogen S.p.A. Antibodies against tenascin-c
JP2008543278A (ja) 2005-05-11 2008-12-04 フィロゲン エスピーエー フィブロネクチンｅｄ−ｂに対する抗体ｌ１９とインターロイキン１２との融合タンパク質
CA2648484A1 (en) 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
ES2402171T3 (es) * 2007-04-02 2013-04-29 Philogen S.P.A. El antígeno ED-A del fibrinógeno está asociado con la neovasculatura de las metástasis tumorales
WO2009013619A2 (en) * 2007-07-25 2009-01-29 Philogen S.P.A The ed-a antigen of fibrinogen is associated with the neovas culature of tumor metastases
PL3281952T3 (pl) * 2007-10-30 2020-11-16 Philogen S.P.A. Antygen związany z reumatoidalnym zapaleniem stawów
US9527907B2 (en) * 2009-01-07 2016-12-27 Philogen S.P.A. Antigens associated with endometriosis, psoriatic arthritis and psoriasis
AU2011307236A1 (en) * 2010-09-29 2013-03-28 Philogen S.P.A. Thiazolidine linker for the conjugation of drugs to antibodies
WO2013014149A1 (en) * 2011-07-27 2013-01-31 Philogen S.P.A. Il-12 immunoconjugate
EP2988784A1 (en) * 2013-04-25 2016-03-02 Philogen S.p.A. Antibody-drug conjugates
CA2910044A1 (en) * 2013-04-26 2014-10-30 Philogen S.P.A. Il4 conjugated to antibodies against extracellular matrix components
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
EA200970909A1 (ru) 2010-10-29
US20130280759A1 (en) 2013-10-24
WO2008120101A3 (en) 2008-12-11
JP2010523541A (ja) 2010-07-15
CN101687923A (zh) 2010-03-31
CA2682851C (en) 2017-01-17
JP5221641B2 (ja) 2013-06-26
EP2142567A2 (en) 2010-01-13
CA2682851A1 (en) 2008-10-09
US9896503B2 (en) 2018-02-20
EA201301224A1 (ru) 2014-07-30
US20130266511A1 (en) 2013-10-10
JP2013121353A (ja) 2013-06-20
EA018985B1 (ru) 2013-12-30
US20100247541A1 (en) 2010-09-30
BRPI0809989B8 (pt) 2021-05-25
EP2142567B1 (en) 2013-01-16
CN103275220B (zh) 2016-01-20
US8263041B2 (en) 2012-09-11
WO2008120101A2 (en) 2008-10-09
US8481684B2 (en) 2013-07-09
EP2653478B1 (en) 2016-10-05
JP5840631B2 (ja) 2016-01-06
KR101515243B1 (ko) 2015-04-24
BRPI0809989A2 (pt) 2015-09-29
ES2402171T3 (es) 2013-04-29
KR20100016094A (ko) 2010-02-12
AU2008234615A1 (en) 2008-10-09
CN101687923B (zh) 2013-06-19
MX2009010639A (es) 2009-10-23
CN103275220A (zh) 2013-09-04
EP2653478A1 (en) 2013-10-23
US9181347B2 (en) 2015-11-10
EA036322B1 (ru) 2020-10-26
US20130040361A1 (en) 2013-02-14
AU2008234615B2 (en) 2013-10-10
BRPI0809989B1 (pt) 2019-10-08
US20160083461A1 (en) 2016-03-24
ES2609813T3 (es) 2017-04-24
HK1184794A1 (zh) 2014-01-30

Similar Documents

Publication Publication Date Title
HK1140217A1 (en) The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases
WO2009013619A3 (en) The ed-a antigen of fibrinogen is associated with the neovas culature of tumor metastases
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
MX2010004726A (es) Antigeno asociado con artritis reumatoide.
SG159458A1 (en) Novel immunoglobulin-binding proteins with improved specificity
CY1112102T1 (el) Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
UA100874C2 (en) Bivalent bispecific antibodies
MX2010006396A (es) Anticuerpos bivalentes, biespecificos.
MA32938B1 (fr) Composes organiques
UA113397C2 (xx) Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3
MX2012003396A (es) Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
IN2014DN10428A (es)
MY151047A (en) Iron (iii)-carbohydrate based phosphate adsorbent
MX2010002783A (es) Proceso e intermediarios para la preparacion de inhibidores de integrasa.
WO2010078945A3 (en) Cancer treatment
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
MX2011013351A (es) Materiales de soporte inorgánicos que contienen compuestos de 3 anillos heterocíclicos.
CY1119492T1 (el) Παραγωγα καρβαμικα/ουριας
TW200728310A (en) Process for the preparation of ferri-succinylcasein
MX2009013069A (es) Tratamiento de leucemia resistente al imatinib.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230404